Vessel wall, not platelet, P2Y12 potentiates early atherogenesis

Cardiovascular Research

Volumn 102, Issue 3, 2014, Pages 429-435

  West, Laura E ^a   Steiner, Tanja ^a   Judge, Heather M ^a   Francis, Sheila E ^a   Storey, Robert F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Atherogenesis; Clopidogrel; P2Y12; Platelet; Ticagrelor

Indexed keywords

APOLIPOPROTEIN E; CLOPIDOGREL; PADGEM PROTEIN; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ADENOSINE; P2RY12 PROTEIN, MOUSE; TICLOPIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA SINUS; ARTICLE; ATHEROGENESIS; ATHEROMA; BLOOD CLOTTING TEST; BLOOD FLOW; BLOOD VESSEL WALL; BONE MARROW TRANSPLANTATION; BRACHIOCEPHALIC TRUNK; CONTROLLED STUDY; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; LIPID DIET; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; ANALOGS AND DERIVATIVES; ANIMAL; ATHEROSCLEROSIS; BLOOD VESSEL; C57BL MOUSE; KNOCKOUT MOUSE; PHYSIOLOGY; THROMBOCYTE;

ADENOSINE; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PLATELETS; BLOOD VESSELS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P-SELECTIN; RECEPTORS, PURINERGIC P2Y12; TICLOPIDINE;

EID: 84901432081     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu028     Document Type: Article

References (39)

1. Libby P. Inflammation in atherosclerosis. Nature 2002;420: 868-874.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340: 115-126.
3. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995;15: 1512-1531.
4. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME et al. Adefinition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1994;14: 840-856.
5. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391: 591-594.
6. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001;103: 1772-1777.
7. Gawaz M, Brand K, Dickfeld T, Pogatsa-MurrayG, Page S, BognerCet al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000;148: 75-85.
8. Massberg S, Vogt F, Dickfeld T, Brand K, Page S, Gawaz M. Activated platelets trigger an inflammatory response and enhance migration of aortic smooth muscle cells. Thromb Res 2003;110: 187-194.
9. Schini-Kerth VB, Bassus S, Fisslthaler B, Kirchmaier CM, Busse R. Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB. Circulation 1997;96: 3888-3896.
10. Bultmann A, Li Z, Wagner S, Peluso M, Schonberger T, Weis Cet al. Impact of glycoprotein VI and platelet adhesion on atherosclerosis-a possible role of fibronectin. J Mol Cell Cardiol 2010;49: 532-542.
11. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003;101: 2661-2666.
12. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002;196: 887-896.
13. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9: 61-67.
14. Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000;110: 925-934.
15. HammCW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H et al. Guidelines ESCCfP. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32: 2999-3054.
16. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345: 494-502.
17. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 1045-1057.
18. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010;56: 1456-1462.
19. Evans DJ, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K et al. Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 2009;119: 116-122.
20. Patil SB, Jackman LE, Francis SE, Judge HM, Nylander S, Storey RF. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima. Arterioscler Thromb Vasc Biol 2010;30: 2385-2391.
21. Wihlborg AK, Wang L, BraunOO, Eyjolfsson A, Gustafsson R, Gudbjartsson Tet al.ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004;24: 1810-1815.
22. Rauch BH, Rosenkranz AC, Ermler S, Bohm A, Driessen J, Fischer JW et al. Regulation of functionally active P2Y12ADPreceptors by thrombin in human smoothmuscle cells and the presence of P2Y12 in carotid artery lesions. Arterioscler Thromb Vasc Biol 2010;30: 2434-2442.
23. Li D, Wang Y, Zhang L, Luo X, Li J, Chen X et al. Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2012;32: E81-e89.
24. van Giezen JJ, Sidaway J, Glaves P, Kirk I, Bjorkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Therapeut 2012;17: 164-172.
25. Hogberg C, Svensson H, Gustafsson R, Eyjolfsson A, Erlinge D. The reversible oralP2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. Int J Cardiol 2010;142: 187-192.
26. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107: 1591-1598.
27. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992;89: 4471-4475.
28. Chamberlain J, Evans D, King A, Dewberry R, Dower S, Crossman D et al. Interleukin-1 beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am J Pathol 2006;168: 1396-1403.
29. Zhang L. Voluntary oral administration of drugs in mice. Protocol Exchange: Nature Publishing Group, 2011.
30. Bolliger D, Szlam F, Suzuki N, Matsushita T, Tanaka KA. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice. Thromb Haemost 2010; 103: 1233-1238.
31. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002;106: 1523-1529.
32. Hechler B, Freund M, Ravanat C, Magnenat S, Cazenave JP, Gachet C. Reduced atherosclerotic lesions in P2Y1/apolipoprotein E double-knockout mice: The contribution of non-hematopoietic-derived P2Y1 receptors. Circulation 2008;118: 754-763.
33. Afek A, Kogan E, Maysel-Auslender S, Mor A, Regev E, Rubinstein A et al. Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. Microvasc Res 2009;77: 364-369.
34. Schulz C, Konrad I, Sauer S, Orschiedt L, Koellnberger M, LorenzRet al. Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. Thromb Haemost 2008;99: 190-195.
35. Grzesk G, Kozinski M, Navarese EP, Krzyzanowski M, Grzesk E, KubicaAet al. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. Thromb Res 2012;130: 65-69.
36. Dubey RK, Gillespie DG, Jackson EK. Cyclic AMP-adenosine pathway induces nitric oxide synthesis in aortic smooth muscle cells. Hypertension 1998;31: 296-302.
37. Smits P, Williams SB, Lipson DE, Banitt P, RongenGA, CreagerMA. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 1995;92: 2135-2141.
38. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96: 60-68.
39. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83: 1774-1777.